Impilo has today signed an agreement to acquire a majority holding in The Fertility Partnership (“TFP”), one of the leading European providers of fertility services, ultrasound pregnancy scans and hormone treatments with activities in the UK and Poland. The group comprises 8 IVF clinics in the UK, which in turn are supported by a network of 27 satellites, thus enabling local patient care; 2 IVF clinics in Poland, the leading independent provider of ultrasound services through a network of 88 ultrasound across the UK; and a nascent hormone treatment business.
- The Fertility Partnership (“TFP”) is one of the leading European providers of fertility services, ultrasound pregnancy scans and hormone treatments present in the UK and Poland
- TFP is the largest UK IVF provider with over 10,000 cycles p.a. every four hours a TFP baby is born in the UK
- With its origins in and continued close connections to some of the UK’s leading universities in fertility-related research, TFP delivers world class patient outcomes based on best-in-class clinical processes
- Impilo acquires a controlling majority holding in TFP, with the clinician founders of the group and the individual founders and owners of the individual clinics retaining a significant minority holding
- Impilo is excited to support TFP’s continued investment in strengthening and expanding the Group’s offering across the UK and Poland and its strategic growth plans into new countries
Impilo has today signed an agreement to acquire a majority holding in The Fertility Partnership (“TFP”), one of the leading European providers of fertility services, ultrasound pregnancy scans and hormone treatments with activities in the UK and Poland. The group comprises 8 IVF clinics in the UK, which in turn are supported by a network of 27 satellites, thus enabling local patient care; 2 IVF clinics in Poland, the leading independent provider of ultrasound services through a network of 88 ultrasound across the UK; and a nascent hormone treatment business.
Impilo is acquiring its majority holding in the group from White Cloud Capital, the clinician founders of the group and clinic level minority shareholders. The clinician founders and clinic level minority shareholders will retain a significant minority holding in the group and their individual clinics respectively.
TFP was founded in 2012 with the merger of Oxford Fertility (a spin-off from Oxford University Hospitals) and IVF Hammersmith (closely associated with Imperial College London Hospitals) and the concomitant injection of growth capital from White Cloud Capital. Over the past seven years the group expanded through further add-on acquisitions, greenfield developments, and expansion into Poland and also adjacent services. TFP is structured as an overarching entity that is the majority or outright owner of the individual clinics, in most of which founding doctors hold a minority ownership, thereby becoming partners with TFP. TFP has grown to be the largest IVF provider in the UK and enjoys the highest patient satisfaction ratings as reported by the HFEA, the UK regulator. In addition, TFP has a strong established foothold in Poland where it is currently the third largest provider. TFP delivers over 10,000 IVF cycles p.a., has revenues of approximately GBP 51 million and employs approx. 600 individuals.
Impilo is a Nordic-based investment company that focuses exclusively on investments in healthcare companies active in the areas of pharmaceuticals, medical technology, healthcare services and other health-related areas. The objective is for the portfolio companies to contribute to the development and improvement of their respective areas and thus contribute to a sustainable society in the longer term. Due to underlying societal and demographic factors, the European IVF market is expected to continue growing in the longer term. TFP’s leading clinical capabilities and patient-centric approach contributed to Impilo identifying the company as an attractive investment opportunity early on.
”We are impressed by TFP’s strong management team and its best-in-class clinical processes and results at the clinic level. The IVF market is growing, and we see great potential in strengthening TFP’s position in both the UK and Poland and establishing a strong foothold in other European countries”, says Hans-Christian Bødker Jensen, Partner at Impilo.
“We are delighted to be partnering with Impilo to continue to develop TFP. We are very proud of what the team has achieved in recent years, developing, acquiring and integrating new clinics and welcoming their respective founders. While we pride ourselves on our inclusive partnership culture, we have also developed a strong central management team that provides strategic leadership and support services and ensures that the group realises available synergies. Impilo is a long-term dedicated healthcare investor that share our values where patient care and experience are at the centre of everything that we do. We are very excited for our patients and staff to continue our growth journey with Impilo.” says Andrew Came, CEO of TFP.
For further information, please contact:
Hans-Christian Bødker Jensen, Partner, Impilo AB, +45 22 70 20 10, hc.bodker@impilo.se
Fredrik Strömholm, Partner, Impilo AB, +46 76 115 10 65, fredrik.stromholm@impilo.se
About Impilo
Impilo is a Nordic-based investment company focused on investments in healthcare companies active in pharmaceuticals, medical technology, healthcare services and other health-related areas. Impilo’s perspective is that the portfolio companies must contribute to a positive development in their fields and thus society in order to be successful long term. Impilo manages over SEK 3.5 billion in capital from leading Nordic and international investors. Larger investors include AP3 (The Third Swedish National Pension Fund), Tryghedsgruppen and Goldman Sachs Asset Management. Learn more about Impilo at www.impilo.se.
About The Fertility Partnership
The Fertility Partnership is a leading European provider of fertility services, ultrasound pregnancy scans and hormone treatments present in the UK and in Poland. The group comprises 8 IVF clinics in the UK, 2 IVF clinics in Poland, 88 ultrasound clinics in the UK, as well as a nascent hormone treatment business. TFP was founded in 2012 through the merger of two IVF clinics and has since expanded through further add-on acquisitions, greenfield developments and expansion into adjacent services. Today it is the largest provider of fertility services in the UK and the third largest in Poland; it also operates the UK’s leading independent provider of ultrasound scanning services. Learn more about TFP at https://www.thefertilitypartnership.com
News
KKR and Impilo announce strategic partnership together with management in rare disease platform Immedica Pharma
Stockholm and London, 23 April 2024 – Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Existing owner, Nordic healthcare investment firm Impilo, will reinvest to become an equal owner alongside KKR. The transaction is subject to customary regulatory and closing conditions.
Impilo invests in Avia Pharma – a leading OTC and Rx pharmaceutical platform
Impilo has closed its investment in Avia Pharma Holding AB, a Sweden-based OTC and Rx pharmaceutical company with presence in the Nordics and Germany. Impilo now partners with two of the co-founders and management of Avia. Our ambition is to build a leading Northern European OTC / Rx platform through organic and inorganic growth.
Loargys® (pegzilarginase) approved in the EU for treatment of arginase 1 deficiency (ARG1-D)
Immedica today announces that the European Commission has granted marketing authorization of Loargys® (pegzilarginase) for the treatment of arginase 1 deficiency (ARG1-D), also known as hyperargininemia, in adults, adolescents and children aged 2 years and older. The approval follows the positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use on October 12.